KURA241220P7500
- 0.10
- -0.05-33.33%
Kura Oncology Newsroom
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $18 to $34
Kura Oncology Analyst Ratings
B of A Securities Maintains Buy on Kura Oncology, Lowers Price Target to $29
Kura Oncology's Strategic Developments and Partnership With Kyowa Kirin Justify Buy Rating, Despite Initial Stock Dip
Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)
Kura Oncology Price Target Cut to $28.00/Share From $32.00 by Jefferies
Kura Oncology Is Maintained at Buy by Jefferies
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
Wedbush Lowers Price Target on Kura Oncology to $34 From $37, Keeps Outperform Rating
BTIG Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Raises Target Price to $37
Strategic Partnerships and Growth Potential Drive Buy Rating for Kura Oncology
JMP Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
Kura Oncology Analyst Ratings
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
Optimistic Buy Rating for Kura Oncology: Ziftomenib's Competitive Edge and Strong Safety Profile
JMP Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32